Analysis of the side effects of Osimertinib/Tagressa: How safe is it in targeted therapy for lung cancer?

Osimertinib/Tagrisso (Osimertinib) is a targeted therapy for patients with EGFR mutations in non-small cell lung cancer (NSCLC). It significantly delays tumor progression and improves patient survival rate by inhibiting EGFR mutations, especially the T790M mutation. However, although osimertinib has shown good clinical efficacy, like all drugs, patients may still experience certain side effects during use.

Common side effects of osimertinib include skin reactions, gastrointestinal discomfort, respiratory problems, and cardiovascular problems. Skin reactions are one of the most common side effects, and patients may experience rash, itching, dryness, or mild skin inflammation. These reactions are usually mild and can be relieved by appropriate skin care and medication in most patients. For some serious skin problems, your doctor may recommend suspending treatment or adjusting the dosage to reduce symptoms.

Gastrointestinal discomfort is also a common side effect of osimertinib, and patients may experience diarrhea, loss of appetite, nausea, and other symptoms. Diarrhea is a common reaction, and some patients may need to take antidiarrheal medications to relieve discomfort. In order to avoid the effects of diarrhea, patients should pay attention to a light diet, avoid overly greasy food, and report any discomfort to their doctor in a timely manner while taking osimertinib.

Osimertinib may also cause some serious side effects, such as interstitial lung disease. Interstitial lung disease is a lung disease that manifests as dyspnea, cough and other symptoms. Although the probability of such side effects is low, once it occurs, medication needs to be stopped immediately and corresponding treatment required. In addition, cardiovascular problems are also side effects that some patients may encounter, manifested as high blood pressure, arrhythmia, etc. Patients need to check their blood pressure and electrocardiogram regularly during treatment.

Reference materials:https://go.drugbank.com/drugs/DB09330